Skip to main content
. 2023 Feb 22;8(4):e156643. doi: 10.1172/jci.insight.156643

Figure 1. Time to termination of adalimumab treatment due to ineffectiveness, stratified by ADA status (discovery cohort: individuals sampled 6–36 months after treatment initiation, n = 784).

Figure 1

Light turquoise: ADA negative (undetectable). Dark turquoise: ADA positive (detectable). Kaplan-Meier survival analysis was used.